Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

RECORD QUARTERLY NET PRODUCT SALES OF $102.7 MILLION ACHIEVED WITHIN TWO YEARS OF OURXDEMVY  LAUNCH, AN INCREASE OF 152% YEAR OVER YEAR

TARSUS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS ACHIEVEMENTS

IRVINE, CALIF., JULY 30, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS), TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST AT 1:30 P.M. PT / 4:30 P.M. ET ON WEDNESDAY, AUGUST 6, 2025, TO REPORT ITS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

TARSUS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, AUGUST 6, 2025

IRVINE, CALIF., MAY 29, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS), TODAY ANNOUNCED THAT MANAGEMENT PLANS TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

TARSUS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

IRVINE, CALIF., MAY 08, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS) TODAY ANNOUNCED THAT MANAGEMENT PLANS TO PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

GREENFIELD, IND. , MAY 5, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THE SALE OF CERTAIN FUTURE TIERED ROYALTIES AND COMMERCIAL MILESTONES ASSOCIATED WITH XDEMVY (LOTILANER OPHTHALMIC SOLUTION) 0.25%, FOR THE HUMAN HEALTH APPLICATION OF LOTILANER, TO FUNDS AFFILIATED WITH BLACKSTONE LIFE SCIENCES AND BLACKSTONE CREDIT & INSURANCE FOR $295 MILLION IN CASH.

ELANCO SELLS ROYALTY AND MILESTONE RIGHTS FOR LOTILANER IN HUMAN HEALTH TO BLACKSTONE; ACCELERATES DEBT PAYDOWN

GENERATED $78.3 MILLION IN NET PRODUCT SALES OF XDEMVY  , AN INCREASE OF 217% YEAR OVER YEAR AND 18% OVER Q4 2024, AND DISPENSED APPROXIMATELY 72,000 BOTTLES TO PATIENTS

TARSUS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS ACHIEVEMENTS

IRVINE, CALIF., APRIL 24, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS), TODAY ANNOUNCED THAT IT WILL HOST A LIVE WEBCAST AT 1:30 P.M. PT / 4:30 P.M. ET ON THURSDAY, MAY 1, 2025, TO REPORT ITS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

TARSUS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, MAY 1, 2025

IRVINE, CALIF., APRIL 22, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS) WILL PRESENT FOUR DISTINCT DATA SETS HIGHLIGHTING THE GLOBAL PREVALENCE AND REAL-WORLD PATIENT BURDEN OF DEMODEX BLEPHARITIS, AS WELL AS THE IMPACT OF XDEMVY (LOTILANER OPHTHALMIC SOLUTION) 0.25% IN ADDRESSING OBJECTIVE MEASURES OF DISEASE AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS) 2025 ANNUAL MEETING, TAKING PLACE APRIL 25-28, 2025, IN LOS ANGELES, CALIF.

TARSUS TO PRESENT SEVERAL SCIENTIFIC ABSTRACTS HIGHLIGHTING THE GLOBAL PREVALENCE OF DEMODEX BLEPHARITIS AND THE CLINICAL IMPACT OF XDEMVY AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY (ASCRS) 2025 ANNUAL MEETING

IRVINE, CALIF., MARCH 12, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS) (THE COMPANY OR TARSUS) TODAY ANNOUNCED THE PRICING OF AN UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 2,808,988 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $44.50 PER SHARE. IN ADDITION, TARSUS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 421,348 SHARES OF ITS COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES PAYABLE BY TARSUS, ARE EXPECTED TO BE APPROXIMATELY $125.0 MILLION, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. THE OFFERING IS EXPECTED TO CLOSE ON MARCH 14, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

TARSUS ANNOUNCES PRICING OF UPSIZED $125.0 MILLION PUBLIC OFFERING

IRVINE, CALIF., MARCH 12, 2025 (GLOBE NEWSWIRE) -- TARSUS PHARMACEUTICALS, INC. (NASDAQ: TARS) (THE COMPANY OR TARSUS) TODAY ANNOUNCED THE COMMENCEMENT OF AN UNDERWRITTEN PUBLIC OFFERING OF $100.0 MILLION OF SHARES OF ITS COMMON STOCK. TARSUS ALSO INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $15.0 MILLION OF SHARES OF ITS COMMON STOCK OFFERED IN THE PROPOSED OFFERING. ALL SHARES IN THE PROPOSED OFFERING ARE TO BE SOLD BY TARSUS. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

Tarsus Pharmaceuticals, Inc.

TARS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Tarsus Pharmaceuticals, Inc.

TARS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TARS